Treace Medical Concepts (TMCI) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $44.5 million, up 6% year-over-year, driven by increased case volumes, product mix shift, and growing surgeon adoption, with over 3,000 active surgeon customers and 150 new additions in H1 2024.

• Net loss widened to $21.2 million ($0.34 per share) from $12.3 million ($0.20 per share) in Q2 2023, reflecting higher operating expenses, strategic investments, and a one-time $2.1 million receivable write-off.

• Cash, cash equivalents, and marketable securities totaled $97 million as of June 30, 2024, with $54 million in outstanding debt.

• The company is preparing to commercialize more than 10 new products, including two minimally invasive surgery (MIS) osteotomy platforms, starting in late 2024 and throughout 2025.

• Strategic investments continue in direct sales expansion, R&D, and product innovation, with ongoing operating losses expected in the near term.

Financial highlights

• Q2 2024 revenue was $44.5 million, a 6% increase over Q2 2023; gross profit was $35.7 million.

• Gross margin for Q2 2024 was 80.2%, down from 81.7% in Q2 2023, but flat sequentially from Q1 2024.

• Operating expenses rose to $57.1 million from $47.3 million year-over-year, reflecting investments in sales, R&D, and innovation.

• Net loss attributable to common stockholders was $21.2 million ($0.34 per share), compared to $12.3 million ($0.20 per share) in Q2 2023.

• Cash and marketable securities totaled $95.1 million as of June 30, 2024.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $201 million–$211 million, representing 7%–13% growth over 2023.

• Adjusted EBITDA for 2024 expected to improve by approximately 50% versus 2023, with positive EBITDA targeted for 2025.

• New product launches in H2 2024, including entry into the MIS osteotomy market, will be limited in scope and are not expected to materially impact 2024 results.